Furthermore the comparable low MHC-I and MHC-II expression levels on the two tumor cell lines rules out improved recognition of B16SLC35A1 by tumor-reactive CD8+ and CD4+ T cells (Figure 1I). This evidence concerns the gene CD4 and neoplasm.